Delta-carboline compound as well as synthesis method and application thereof

Through the 'three-step one-pot' synthesis strategy without metal catalysis, the existing δ-carboline synthesis methods are solved, and the efficient and highly selective synthesis of δ-carboline compounds is achieved, and the Its biological activity in anti-leukemia and anti-tumor.

CN118978527APending Publication Date: 2024-11-19CHENGDU INSTITUTE OF BIOLOGY CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411048103.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing delta-carboline synthesis method is complicated, the use of transition metal catalysis, the reaction conditions are harsh, the selectivity is poor, the yield is low, the substrate range is limited, the lack of high selectivity, metal-free catalysis, the substrate is cheap and easy to obtain, and the conditions are mild method.

Method used

Using the 'three-step one-pot' synthesis strategy, using indole propanol and activated hydroxylamine as raw materials, δ-carbazide derivatives are synthesized under the action of organic solvents and Bronst acid, and then under the action of oxidants and alkalis. line compounds achieve metal-free catalysis, efficient and highly selective synthesis.

Benefits of technology

A series of δ-carboline compounds were synthesized efficiently and highly selectively, with high yield and simple operation, providing a variety of δ-carboline derivatives and demonstrating better anti-leukemia and Anti-tumor biological activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_7
    Figure SMS_7
Patent Text Reader

Abstract

The invention relates to the technical field of organic chemistry and medicinal chemistry, in particular to a delta-carboline compound as well as a synthesis method and application thereof. According to the specific technical scheme, the synthetic method of the delta-carboline compound comprises the following steps: stirring an indole hydroxylamine derivative for 0-96 hours under the action of an organic solvent and Bronsted acid, and cooling to room temperature; and stirring for 0-96 hours under the action of an oxidizing agent and alkali to obtain the delta-carboline compound. The invention solves the problems of lack of structural diversity of delta-carboline, poor product selectivity, use of transition metal for catalysis in the reaction process and the like in the prior art.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of organic chemistry and medicinal chemistry, and in particular to delta-carboline compounds and synthesis methods and applications thereof. Background Art

[0002] Carboline is a pyrido[x,yb]indole structure. It is divided into four isomers, α, β, γ, and δ-carboline, according to the position of the N atom in the pyridine ring. This type of nitrogen heterocyclic ring has a very wide range of biological activities. Due to the limited synthesis methods, δ-carboline (5H-pyrrolo[3,2-b]indole) is the least studied of the four types of carbolines, but its unique structure is the skeleton structure of a large number of natural products, functional active molecules, and functional material molecules. In vitro biological activity studies have shown that molecules containing the δ-carboline skeleton have a wide range of biological activities, such as antibacterial, anti-inflammatory, anti-tumor, anti-malarial, antiviral, cytotoxic activity, lowering blood sugar, and telomerase inhibition. In addition, δ-carboline compounds are used in luminescent materials. Therefore, the research on δ-carboline has great development prospects, and the construction and modification of δ-carboline has always been one of the research hotspots of synthetic chemists and medicinal chemists.

[0003] In the early days, δ-carboline compounds had to be extracted from plants, but this method had many problems such as long separation cycle, complex composition, high separation difficulty, and large demand for raw materials. So far, the existing synthesis methods of δ-carboline mainly include the following three strategies: 1) Synthesizing δ-carboline by constructing a pyrrole core through the formation of CC bonds or CN bonds, such as intramolecular cross-coupling reactions catalyzed by transition metal complexes (Cook, JM, et al. Org. Biomol. Chem., 2015, 13, 10705-10715.); 2) Synthesizing δ-carboline by constructing a pyridine ring, such as the I2-promoted cycloaddition of indole oxime esters (Yao, CF, et al. Chem. Commun., 2017, 53, 1676-1679.); 3) Synthesizing δ-carboline by simultaneously constructing multiple rings, such as the [2+2+2] cycloaddition reaction of alkynamide cyanide and alkynamide (Tang. Y., et al. J. Org. Chem. 2018, 83, 13308-13324).

[0004] Most of the reported methods have the disadvantages of cumbersome steps, use of transition metal catalysis, harsh reaction conditions, poor selectivity, low yield, limited substrate range, and difficult substrate synthesis. So far, there are few reports on the synthesis methods and activity studies of δ-carboline with high selectivity, metal-free catalysis, wide substrate range, and mild reaction conditions. Summary of the invention

[0005] In view of the deficiencies of the prior art, the present invention provides δ-carboline compounds and synthesis methods and applications, which solve the problems of the prior art such as lack of structural diversity of δ-carboline, poor product selectivity, and use of transition metal catalysis in the reaction process.

[0006] To achieve the above objectives, the present invention is implemented through the following technical solutions:

[0007] The present invention discloses a δ-carboline compound, the general structural formula of which is shown in the following (I):

[0008]

[0009] Among them, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 are any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group;

[0010] R 5 It is any one of a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a sulfonyl group, an acyl group, a carbonyl group, and an allyl group.

[0011] Preferably, when the R 1 and / or R 2 and / or R 3 and / or R 4 and / or R 6 and / or R 7 and / or R 8 When each of the above R is alkyl, fluoroalkyl, aryl, fluoroaryl, heteroaryl, fluoroheteroaryl, hydroxyl, alkoxy, aryl ether, heteroaryl ether, thiol, alkyl thioether, aryl thioether, heteroaryl thioether, amino, alkylamino, arylamino, heteroarylamino, ester, acyl, amide, carbonyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, sulfonyl, sulfone and sulfoxide, the above R 1 and / or R 2 and / or R 3 and / or R 4 and / or R 6 and / or R 7 and / or R 8 Can be represented by one or more independent R X substituted by a substituent;

[0012] When R 5 When R is any one of an alkyl group, an aryl group, a heteroaryl group, a sulfonyl group, an acyl group, a carbonyl group, and an allyl group, 5 Can be represented by one or more independent R X replace;

[0013] The R X It is any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group.

[0014] Preferably, when the R X When R is any one of alkyl, fluoroalkyl, aryl, fluoroaryl, heteroaryl, fluoroheteroaryl, hydroxyl, alkoxy, aryl ether, heteroaryl ether, thiol, alkyl thioether, aryl thioether, heteroaryl thioether, amino, alkylamino, arylamino, heteroarylamino, ester, acyl, amide, carbonyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, sulfonyl, sulfone, and sulfoxide, X It may be substituted by one or more hydrogen atoms, alkyl, fluoroalkyl, aryl, fluoroaryl, heteroaryl, fluoroheteroaryl, hydroxyl, alkoxy, aryl ether, heteroaryl ether, thiol, alkyl thioether, aryl thioether, heteroaryl thioether, amino, alkylamino, arylamino, heteroarylamine, ester, acyl, amide, carbonyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, sulfonyl, sulfone and sulfoxide.

[0015] Correspondingly, the synthesis method of δ-carboline compounds comprises the following steps:

[0016] (1) stirring an indolehydroxylamine derivative in the presence of an organic solvent and a Bronsted acid for 0 to 96 hours, and cooling to room temperature;

[0017] (2) The reaction solution of step (1) is stirred for 0 to 96 hours under the action of an oxidant and a base to obtain a δ-carboline compound.

[0018] Preferably, the synthesis process of the indolehydroxylamine derivative is: indolepropanol, activated hydroxylamine derivative, organic phosphine, and azodicarboxylate are stirred in an organic solvent for 0 to 96 hours, and the obtained product is concentrated to dryness at low temperature.

[0019] Preferably, the equivalent ratio of indolepropanol, activated hydroxylamine derivative, organic phosphine, and azodicarboxylic acid ester is 1:0.01-20:0.01-20:0.01-20, the concentration of the organic solvent is 0.001-100 mol / L, and the reaction temperature is -100-200°C;

[0020] In step (1), the equivalent ratio of the indolehydroxylamine derivative to the Bronsted acid is 1:0.01-20, the concentration of the organic solvent is 0.001-100 mol / L, and the reaction temperature is -100-200°C;

[0021] In step (2), the equivalent ratio of the base to the indolehydroxylamine derivative is 1:0.01-20, and the reaction temperature is -100-200°C.

[0022] Preferably, the structural formula of the activated hydroxylamine derivative is:

[0023] Among them, R 9 is any one of acyl, carbonyl, and sulfonyl; R 10 Any of sulfonyl and acyl;

[0024] The organic phosphine is any one of triaryl phosphine, triheteroaryl phosphine, trialkyl phosphine, etc., or a mixture of any proportion of several of them;

[0025] The azodicarboxylic acid ester is any one of dialkyl azodicarboxylate, diaryl azodicarboxylate and diheteroaryl azodicarboxylate or a mixture of any proportions of the above.

[0026] Preferably, when the R 9 When R is any one of acyl, carbonyl, and sulfonyl, 9 Can be one or more independent R X Replacement; when the R 10 When R is a sulfonyl group or an acyl group, 10 Can be one or more independent R X replace;

[0027] And / or, the aryl, heteroaryl and alkyl groups in the triarylphosphine, triheteroarylphosphine and trialkylphosphine may be replaced by one or more independently R X replace;

[0028] And / or, the alkyl, aryl, and heteroaryl groups in the dialkyl azodicarboxylate, diaryl azodicarboxylate, and diheteroaryl azodicarboxylate may be replaced by one or more independently selected R X replace;

[0029] The R XIt is any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group.

[0030] Preferably, the Bronsted acid is one or a mixture of any proportion of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, benzoic acid, and sulfonic acid;

[0031] The base is any one of carbonate, bicarbonate, acetate, phosphate, hydrogen phosphate, potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, triethylamine, diisopropylethylamine, DBU, triarylamine, triheteroarylamine or any mixture thereof in any proportion;

[0032] The organic solvent is any one of 2,2,2-trifluoroethanol, 2,2,2-trichloroethanol, 1,1,1,3,3,3-hexafluoro-2-propanol, chloroethanol, 2,2-dichloroethanol, dichloromethane, chloroform, acetonitrile, methanol, ethanol, tert-butanol, isopropanol, benzene, toluene, tetrahydrofuran, N,N-dimethylformamide, DMSO, 1,4-dioxane, 2-methyl-tetrahydrofuran, ether, and tert-butyl methyl ether, or a mixture of several solvents in any proportion.

[0033] The oxidant is any one of O2, air, TEMPO, nitrogen oxides similar to TEMPO, ammonium oxide salts of nitrogen oxides, t-BuOOH, (t-BuO)2, NaOCl, diacetyl iodobenzene, bistrifluoroacetyl iodobenzene, DDQ, tetrachlorobenzoquinone, MnO2, SeO2, ammonium cerium nitrate, nitric acid, Pd / C and nitrogen oxides of amines; except O2 and air, the equivalent ratio of the oxidant to the indolehydroxylamine derivative is 1:0.01 to 20.

[0034] Correspondingly, a pharmaceutical composition comprises the above compound or the compound synthesized by the above synthesis method, or its stereoisomer, tautomer or salt, or its prodrug molecule and a medically acceptable carrier.

[0035] Correspondingly, the above compound or the compound synthesized by the above synthesis method or the above pharmaceutical composition is used in the preparation of drugs for treating leukemia, cancer or tumor.

[0036] The present invention has the following beneficial effects:

[0037] 1. The present invention adopts a "three-step one-pot" synthesis strategy, using indolepropanol and activated hydroxylamine as raw materials to efficiently and highly selectively synthesize a series of δ-carboline compounds. The entire synthesis process has the advantages of no metal catalysis, cheap and readily available substrates, mild conditions, high yield, good selectivity, and simple operation.

[0038] 2. The present invention can further efficiently and highly selectively synthesize delta-carboline derivatives with different substitutions on the pyridine ring by changing the substitution site (C2 or C3) of propanol on indole.

[0039] 3. Since the nitro, aldehyde, cyano, allyl and the like in the product can be further converted into other types of groups through simple reactions, the present invention can provide an irreplaceable route for the diverse synthesis and modification of δ-carboline derivatives.

[0040] 4. Some of the delta-carboline derivatives obtained by the present invention exhibit good anti-leukemia biological activity and broad anti-tumor activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 The graphs show the cytotoxic activity of each compound against tumor cells and cancer cells. DETAILED DESCRIPTION

[0042] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0043] Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art.

[0044] 1. The present invention discloses a δ-carboline compound, the general structural formula of which is shown in the following (I):

[0045]

[0046] Among them, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8are any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group;

[0047] R 5 It is any one of a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a sulfonyl group, an acyl group, a carbonyl group, and an allyl group.

[0048] Furthermore, when the R 1 and / or R 2 and / or R 3 and / or R 4 and / or R 6 and / or R 7 and / or R 8 When each of the above R is alkyl, fluoroalkyl, aryl, fluoroaryl, heteroaryl, fluoroheteroaryl, hydroxyl, alkoxy, aryl ether, heteroaryl ether, thiol, alkyl thioether, aryl thioether, heteroaryl thioether, amino, alkylamino, arylamino, heteroarylamino, ester, acyl, amide, carbonyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, sulfonyl, sulfone and sulfoxide, the above R 1 and / or R 2 and / or R 3 and / or R 4 and / or R 6 and / or R 7 and / or R 8 Can be represented by one or more independent R X substituted by a substituent;

[0049] When R 5 When R is any one of an alkyl group, an aryl group, a heteroaryl group, a sulfonyl group, an acyl group, a carbonyl group, and an allyl group, 5 Can be represented by one or more independent R X replace;

[0050] The R X It is any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group.

[0051] Furthermore, when the R XWhen R is any one of alkyl, fluoroalkyl, aryl, fluoroaryl, heteroaryl, fluoroheteroaryl, hydroxyl, alkoxy, aryl ether, heteroaryl ether, thiol, alkyl thioether, aryl thioether, heteroaryl thioether, amino, alkylamino, arylamino, heteroarylamino, ester, acyl, amide, carbonyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, sulfonyl, sulfone, and sulfoxide, X It may be substituted by one or more hydrogen atoms, alkyl, fluoroalkyl, aryl, fluoroaryl, heteroaryl, fluoroheteroaryl, hydroxyl, alkoxy, aryl ether, heteroaryl ether, thiol, alkyl thioether, aryl thioether, heteroaryl thioether, amino, alkylamino, arylamino, heteroarylamine, ester, acyl, amide, carbonyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, sulfonyl, sulfone and sulfoxide.

[0052] 2. The present invention discloses a method for synthesizing delta-carboline compounds, and the specific steps are as follows:

[0053] (1) stirring indolepropanol, activated hydroxylamine derivative, organic phosphine and azodicarboxylic acid ester in an organic solvent for 0 to 96 hours, and concentrating the obtained product to dryness at low temperature; wherein the equivalent ratio of indolepropanol, activated hydroxylamine derivative, organic phosphine and azodicarboxylic acid ester is 1:0.01 to 20:0.01 to 20:0.01 to 20, the concentration of the organic solvent is 0.001 to 100 mol / L, and the reaction temperature is -100 to 200°C;

[0054] Specifically: the structural formula of the activated hydroxylamine derivative is:

[0055] Among them, R 9 is any one of acyl, carbonyl, and sulfonyl; R 10 any one of sulfonyl and acyl; further, when the R 9 When R is any one of acyl, carbonyl, and sulfonyl, 9 Can be one or more independent R X Replacement; when the R 10 When R is a sulfonyl group or an acyl group, 10 Can be one or more independent R X replace.

[0056] The organic phosphine is any one of triaryl phosphine, triheteroaryl phosphine, trialkyl phosphine, etc. or a mixture of any proportion of several thereof; further, the aryl, heteroaryl, and alkyl groups in the triaryl phosphine, triheteroaryl phosphine, and trialkyl phosphine may be replaced by one or more independent R X replace.

[0057] Specifically: the structural formula of the organic phosphine is Among them, R13 , R 14 , R 15 R is any one of an alkyl group, an aryl group, and a heteroaryl group. 13 , R 14 , R 15 can be the same or different. 13 , R 14 , R 15 The aryl, heteroaryl, and alkyl groups in the X replace.

[0058] The azodicarboxylic acid ester is any one of dialkyl azodicarboxylate, diaryl azodicarboxylate, and diheteroaryl azodicarboxylate, or a mixture of any proportion of the above-mentioned dialkyl azodicarboxylate, diaryl azodicarboxylate, and diheteroaryl azodicarboxylate; further, the alkyl, aryl, and heteroaryl groups in the dialkyl azodicarboxylate, diaryl azodicarboxylate, and diheteroaryl azodicarboxylate may be independently substituted with one or more R X replace.

[0059] Specifically: the structural formula of the azodicarboxylic acid ester is Among them, R 11 , R 12 is any one of an alkyl group, an aryl group, or a heteroaryl group, and R 11 , R 12 can be the same or different. Further, R 11 , R 12 Can be represented by one or more independent R X replace.

[0060] The R X It is any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group.

[0061] (2) The crude product obtained in step (1) is stirred for 0 to 96 hours in the presence of an organic solvent and a Bronsted acid, and then cooled to room temperature; wherein the equivalent ratio of the crude product to the Bronsted acid is 1:0.01 to 20, the concentration of the organic solvent is 0.001 to 100 mol / L, and the reaction temperature is -100 to 200°C; the Bronsted acid is an organic or inorganic acid, including but not limited to a mixture of one or more of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, benzoic acid, and sulfonic acid in any proportion.

[0062] (3) The reaction solution of step (2) is stirred for 0 to 96 hours under the action of an oxidant and a base, and indolepropanol can be converted into a δ-carboline compound by the above three-step one-pot method. The equivalent ratio of the base to the indolehydroxylamine derivative is 1:0.01 to 20, and the reaction temperature is -100 to 200°C.

[0063] The oxidant is any one of O2 (balloon), air (open reaction), TEMPO, nitrogen oxides similar to TEMPO, ammonium oxide salts of nitrogen oxides, t-BuOOH, (t-BuO)2, NaOCl, iodobenzene diacetate, bistrifluoroacetyl iodobenzene, DDQ, tetrachlorobenzoquinone, MnO2, SeO2, cerium ammonium nitrate, nitric acid, Pd / C and nitrogen oxides of amines. Except for O2 and air, the equivalent ratio of the oxidant to the indolehydroxylamine derivative is 1:0.01-20.

[0064] The base is an organic or inorganic base, including but not limited to any one of carbonate, bicarbonate, acetate, phosphate, hydrogen phosphate, potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, triethylamine, diisopropylethylamine, DBU, triarylamine, triheteroarylamine or a mixture of any proportions thereof.

[0065] Further, the organic solvent is any one of 2,2,2-trifluoroethanol, 2,2,2-trichloroethanol, 1,1,1,3,3,3-hexafluoro-2-propanol, chloroethanol, 2,2-dichloroethanol, dichloromethane (DCM), chloroform (CHCl3), acetonitrile (MeCN), methanol (MeOH), ethanol (EtOH), tert-butyl alcohol (t-BuOH), isopropanol (i-PrOH), benzene (PhH), toluene (toluene), tetrahydrofuran (THF), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,4-dioxane, 2-methyl-tetrahydrofuran (2-MeTHF), ether, and tert-butyl methyl ether, or a mixture of several solvents in any proportion.

[0066] 2.1 As one embodiment, indolepropanol is selected from indole 3-substituted indolepropanol and synthesized according to the above-mentioned synthesis method.

[0067] The synthetic route is as follows:

[0068]

[0069] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8The same as the group defined in the above general structural formula (I). 9 ~R 15 See above for specific synthesis steps.

[0070] 2.2 As another embodiment, indolepropanol is selected from indole 2-substituted indole propanol and synthesized according to the above synthesis method.

[0071] The synthetic route is as follows:

[0072]

[0073] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 The same as the group defined in the above general structural formula (I). 9 ~R 15 See above for specific synthesis steps.

[0074] Since the reaction involves an intermediate of an indolehydroxylamine derivative, the following methods 2.3 and 2.4, which use the intermediate of an indolehydroxylamine derivative as a raw material, are also within the scope of protection of the present invention.

[0075] 2.3 The present invention provides a δ-carboline derivative and a method for synthesizing the same. The synthesis process is as follows: (1) stirring an indole hydroxylamine derivative substituted at the 3-position of indole in the presence of an organic solvent and a Bronsted acid within a certain temperature range for 0 to 96 hours; (2) stirring the reaction solution of step (1) within a certain temperature range for 0 to 96 hours under the presence of an oxidant and a base. By using the above two-step one-pot strategy, indole propanol can be converted into a δ-carboline compound. The synthesis route is as follows:

[0076]

[0077] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 The same as the group defined in the above general structural formula (I). 9 , R 10 See above for specific synthesis steps.

[0078] 2.4 The present invention provides a δ-carboline derivative and a method for synthesizing the same. The synthesis process is as follows: (1) stirring an indole hydroxylamine derivative substituted at the 2-position of indole in the presence of an organic solvent and a Bronsted acid within a certain temperature range for 0 to 96 hours; (2) stirring the reaction solution of step (1) within a certain temperature range for 0 to 96 hours under the presence of an oxidant and a base. By using the above two-step one-pot strategy, indole propanol can be converted into a δ-carboline compound. The synthesis route is as follows:

[0079]

[0080] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 The same as the group defined in the above general structural formula (I). 9 , R 10 See above for specific synthesis steps.

[0081] 3. A pharmaceutical composition comprising the above compound or a compound synthesized by the above synthesis method, or its stereoisomer, tautomer or salt, or its prodrug molecule and a medically acceptable carrier.

[0082] 4. Use of the above compound, the compound synthesized by the above synthesis method, or the above pharmaceutical composition in the preparation of drugs for treating leukemia, cancer or tumors.

[0083] In order to further illustrate the synthesis of the δ-carboline compounds in the present invention, the present invention selectively synthesized the following substances, and described the synthesis process of each compound in combination with specific examples.

[0084]

[0085] Example 1 Synthesis of 4-(4-methoxyphenyl)-5H-pyrido[3,2-b]indole (W1)

[0086] The synthesis process is:

[0087] (1) Add 3-(3-indolyl)-3-(4-methoxyphenyl)-1-propanol (84 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and a white solid is produced. Filter, collect the filtrate, and concentrate to dryness at low temperature.

[0088] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0089] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 4-(4-methoxyphenyl)-5H-pyrido[3,2-b]indole (39 mg, 47%).

[0090] The reaction equation is:

[0091]

[0092] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0093] 1 H NMR (600MHz, DMSO-d6) δ11.36(s,1H),8.49(d,J=4.8Hz,1H),8.21(d,J=7.8Hz,1H),7.77(d,J=8.6Hz,2H),7.6 1(d,J=8.1Hz,1H),7.50(t,J=7.5Hz,1H),7.40(d,J=4.8Hz,1H),7.26(t,J=7.4Hz,1H),7.18(d,J=8.6Hz,2H). 13 C NMR(151MHz,DMSO-d6)δ159.7,141.9,141.7,141.1,130.9,130.2,129.7,128.4 ,127.4,121.7,120.1,119.5,118.9,114.7,112.1,55.3.ESI-HRMS(m / z):[M+H] + Calculate for C 18H 15 N2O:275.1179; found:275.1176.

[0094] Example 2 Synthesis of 4-(3-bromophenyl)-5H-pyrido[3,2-b]indole (W2)

[0095] The synthesis process is:

[0096] (1) Add 3-(3-indolyl)-3-(3-bromophenyl)-1-propanol (99 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and produce a white solid, which is filtered and the filtrate is collected and concentrated to dryness at low temperature.

[0097] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0098] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 4-(3-bromophenyl)-5H-pyrido[3,2-b]indole (72 mg, 75%).

[0099] The reaction equation is:

[0100]

[0101] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0102] 1 H NMR (400MHz, DMSO-d6) δ11.47(s,1H),8.49(d,J=4.9Hz,1H),8.18(d,J=7.8Hz,1H),7.92(t,J=4Hz,1H),7.78–7 .76(m,1H),7.71–7.69(m,1H),7.58–7.52(m,2H),7.50–7.47(m,1H),7.42(d,J=4.9Hz,1H),7.26–7.21(m,1H). 13C NMR(151MHz,DMSO-d6)δ142.2,141.7,141.2,138.6,131.5,131.3,131.0,130.1 ,129.5,127.6,122.5,121.6,120.2,119.7,119.4,112.2.ESI-HRMS(m / z):[M+H] + Calculate for C 17 H 12 BrN2:323.0178; found:323.0178.

[0103] Example 3 Synthesis of 4-(2-chlorophenyl)-5H-pyrido[3,2-b]indole (W3)

[0104] The synthesis process is:

[0105] (1) Add 3-(3-indolyl)-3-(2-chlorophenyl)-1-propanol (86 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl) azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and a white solid is produced. Filter, collect the filtrate, and concentrate to dryness at low temperature.

[0106] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0107] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 4-(2-chlorophenyl)-5H-pyrido[3,2-b]indole (48 mg, 58%).

[0108] The reaction equation is:

[0109]

[0110] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0111] 1H NMR (400MHz, DMSO-d6) δ11.28(s,1H),8.53(d,J=4.8Hz,1H),8.23(d,J=7.8Hz,1H),7.72(d,J =7.6Hz,1H),7.61–7.55(m,3H),7.54–7.48(m,2H),7.32(d,J=4.8Hz,1H),7.29–7.24(m,1H). 13 C NMR(101MHz,DMSO-d6)δ141.6,141.0,140.9,135.1,132.3,131.6,130.8,130.4,12 9.9,129.0,127.7,127.6,121.4,120.5,120.1,119.5,111.9.ESI-HRMS(m / z):[M+H] + Calculate for C 17 H 12 ClN2:279.0684; found:279.0682.

[0112] Example 4 Synthesis of 4-(2-thienyl)-5H-pyrido[3,2-b]indole (W4)

[0113] The synthesis process is:

[0114] (1) Add 3-(3-indolyl)-3-(2-thienyl)-1-propanol (77 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl) azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and produce a white solid, which is filtered and the filtrate is collected and concentrated to dryness at low temperature.

[0115] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0116] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 4-(2-thienyl)-5H-pyrido[3,2-b]indole (45 mg, 60%).

[0117] The reaction equation is:

[0118]

[0119] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0120] 1 H NMR (400MHz, DMSO-d6) δ11.41(s,1H),8.48(d,J=4.9Hz,1H),8.21(d,J=7.8Hz,1H),7.91(d,J=3.2Hz,1H),7 .85(d,J=5.0Hz,1H),7.69(d,J=8.2Hz,1H),7.55(t,J=6.8Hz,2H),7.40–7.38(m,1H),7.29(t,J=7.4Hz,1H). 13 C NMR(101MHz,DMSO-d6)δ142.7,141.6,141.2,137.9,128.8,128.7,127.8,12 7.7,127.6,124.0,121.6,120.1,119.9,117.8,112.4.ESI-HRMS(m / z):[M+H] + Calculate for C 15 H 11 N2S:251.0637; found:251.0636.

[0121] Example 5 Synthesis of 8-bromo-4-phenyl-5H-pyrido[3,2-b]indole (W5)

[0122] The synthesis process is:

[0123] (1) Add 3-(3-(5-bromo-1H-indolyl))-3-phenyl-1-propanol (99 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and produce a white solid, which is filtered and the filtrate is collected and concentrated to dryness at low temperature.

[0124] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0125] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 8-bromo-4-phenyl-5H-pyrido[3,2-b]indole (65 mg, 67%).

[0126] The reaction equation is:

[0127]

[0128] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0129] 1 H NMR (600 MHz, DMSO-d6)δ 1 H NMR(600MHz,DMSO-d6)δ11.59(s,1H),8.54(d,J=4.8Hz,1H),8.32–8.31(m,1H),7.7 9(d,J=7.5Hz,2H),7.61(t,J=7.8Hz,3H),7.57–7.51(m,2H),7.47(d,J=4.8Hz,1H). 13 CNMR(101MHz,DMSO-d6)δ142.3,140.8,139.7,135.9,131.6,130.8,129.9,12 9.3,128.8,128.4,123.4,122.3,120.0,114.3,111.7.ESI-HRMS(m / z):[M+H] + Calculate for C 18 H 12 F3N2O:232.0178; found:232.0160.

[0130] Example 6 Synthesis of 8-methoxy-4-phenyl-5H-pyrido[3,2-b]indole (W6)

[0131] The synthesis process is:

[0132] (1) 3-(2-(5-methoxy-1H-indolyl))-3-phenyl-1-propanol (84 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) were added to a reaction tube, and the gas was replaced with nitrogen. Tetrahydrofuran (3 mL) was added and stirred at 0°C for 4 to 8 h. The mixture was then concentrated to dryness at low temperature, and dichloromethane (3 mL) was added to produce a white solid, which was filtered and the filtrate was collected and concentrated to dryness at low temperature.

[0133] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0134] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 8-methoxy-4-phenyl-5H-pyrido[3,2-b]indole (56 mg, 68%).

[0135] The reaction equation is:

[0136]

[0137] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0138] 1 H NMR (400MHz, DMSO-d6) δ11.25(s,1H),8.50(d,J=4.8Hz,1H),7.82(d,J=7.2Hz,2H),7.70(d,J=2.4Hz,1H),7.63 (t,J=7.5Hz,2H),7.53(dd,J=14.9,8.1Hz,2H),7.43(d,J=4.8Hz,1H),7.16(dd,J=8.8,2.5Hz,1H),3.88(s,3H). 13 C NMR(101MHz,DMSO-d6)δ153.6,141.9,141.3,136.3,136.0,131.0,130.8,129.2 ,128.6,128.4,121.9,119.0,117.4,113.1,101.7,55.5.ESI-HRMS(m / z):[M+H] + Calculate for C18 H 15 N2O:275.1179; found:275.1181.

[0139] Example 7 Synthesis of 5-methyl-4-phenyl-pyrido[3,2-b]indole (W7)

[0140] The synthesis process is:

[0141] (1) Add 3-(1-methylindolyl)-3-phenyl-1-propanol (80 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and produce a white solid, which is filtered and the filtrate is collected and concentrated to dryness at low temperature.

[0142] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4-8 h under nitrogen protection, and then cooled to room temperature.

[0143] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 5-methyl-4-phenyl-pyrido[3,2-b]indole (60 mg, 78%).

[0144] The reaction equation is:

[0145]

[0146] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0147] 1 H NMR (400MHz, DMSO-d6) δ8.50(d,J=4.7Hz,1H),8.28(d,J=7.7Hz,1H),7.65–7.55(m,7H),7.33(t,J=7.2Hz,1H),7.27(d,J=4.7Hz,1H),3.42(s,3H). 13C NMR(101MHz,DMSO-d6)δ142.4,141.7,141.0,137.3,132.5,131.2,129.5,128.4 ,128.3,127.9,122.0,121.3,120.1,119.9,110.0,32.4.ESI-HRMS(m / z):[M+H] + Calculate for C 18 H 14 N2:259.1230; found:259.1229.

[0148] Example 8 Synthesis of 8-methoxy-5-methyl-4-phenyl-pyrido[3,2-b]indole (W8) The synthesis process is:

[0149] (1) Add 3-(5-methoxy-1-methylindolyl)-3-phenyl-1-propanol (89 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and produce a white solid, which is filtered and the filtrate is collected and concentrated to dryness at low temperature.

[0150] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0151] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 8-methoxy-5-methyl-4-phenyl-pyrido[3,2-b]indole (47 mg, 54%).

[0152] The reaction equation is:

[0153]

[0154] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0155] 1H NMR (600MHz, DMSO-d6) δ8.46(d,J=4.7Hz,1H),7.75(d,J=2.5Hz,1H),7.57–7.53(m,6H),7.24–7.22(m,2H),3.89(s,3H),3.39(s,3H). 13 C NMR(151MHz,DMSO-d6)δ153.9,141.5,140.6,137.4,137.3,132.5,131.7,129.4,1 28.5,128.3,121.9,121.6,117.4,111.1,101.9,55.6,32.4.ESI-HRMS(m / z):[M+H] + Calculate for C 19 H 16 N2O:289.1335; found:289.1338.

[0156] Example 9 Synthesis of 3,5-dimethyl-4-phenyl-pyrido[3,2-b]indole (W9)

[0157] The synthesis process is:

[0158] (1) Add 2-methyl-3-(1-methylindolyl)-3-phenyl-1-propanol (84 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and a white solid is produced. Filter, collect the filtrate, and concentrate to dryness at low temperature.

[0159] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0160] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 3,5-dimethyl-4-phenyl-pyrido[3,2-b]indole (60 mg, 78%).

[0161] The reaction equation is:

[0162]

[0163] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0164] 1 H NMR (400MHz, DMSO-d6) δ8.50(d,J=4.7Hz,1H),8.28(d,J=7.7Hz,1H),7.65–7.55(m,7H),7.33(t,J=7.2Hz,1H),7.27(d,J=4.7Hz,1H),3.42(s,3H). 13 C NMR(101MHz,DMSO-d6)δ142.4,141.7,141.0,137.3,132.5,131.2,129.5,128.4 ,128.3,127.9,122.0,121.3,120.1,119.9,110.0,32.4.ESI-HRMS(m / z):[M+H] + Calculate for C 18 H 14 N2:259.1230; found:259.1229.

[0165] Example 10 Synthesis of 8-methoxy-5H-pyrido[3,2-b]indole (W10)

[0166] The synthesis process is:

[0167] (1) Add 3-(5-methoxyindolyl)-1-propanol (62 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and a white solid is produced. Filter, collect the filtrate, and concentrate to dryness at low temperature.

[0168] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0169] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 8-methoxy-5H-pyrido[3,2-b]indole (18 mg, 31%).

[0170] The reaction equation is:

[0171]

[0172] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0173] 1 H NMR (400MHz, DMSO-d6) δ11.20(s,1H),8.38(d,J=4.5Hz,1H),7.81(d,J=8.2Hz,1H),7.63(d,J=2.3H z,1H),7.45(d,J=8.8Hz,1H),7.32(dd,J=8.2,4.6Hz,1H),7.11(dd,J=8.8,2.5Hz,1H),3.83(s,3H). 13 C NMR(101MHz,DMSO-d6)δ153.4,141.0,140.7,135.4,133.5,121.8,120.0,118.0,117.2,112.6,101.8,55.5.ESI-HRMS(m / z):[M+H] + Calculate for C 12 H 11 N2O:199.0866; found:199.0856.

[0174] Example 11 Synthesis of 5-methyl-5H-pyrido[3,2-b]indole (W11)

[0175] The synthesis process is:

[0176] (1) Add 3-(2-(1-methylindolyl))-1-propanol (57 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and produce a white solid, which is filtered and the filtrate is collected and concentrated to dryness at low temperature.

[0177] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0178] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 5-methyl-5H-pyrido[3,2-b]indole (29 mg, 64%).

[0179] The reaction equation is:

[0180]

[0181] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0182] 1 H NMR (400MHz, CDCl3) δ8.55 (dd, J=4.7, 1.1Hz, 1H), 8.40 (d, J=7.8Hz, 1H), 7.66 (dd, J=8. 3,1.0Hz,1H),7.59–7.55(m,1H),7.43(d,J=8.2Hz,1H),7.37–7.31(m,2H),3.83(s,3H). 13 C NMR(101MHz, CDCl3)δ141.9,141.6,134.5,127.9,122.1,121.0,120.05,120.01,115.5,108.9,29.1.ESI-HRMS(m / z):[M+H] + Calculate for C 12 H 11 N2:183.0917; found:183.0924.

[0183] Example 12 Synthesis of 3-allyl-5-methyl-5H-pyrido[3,2-b]indole (W12)

[0184] The synthesis process is:

[0185] (1) Add 2-(2-(1-methylindolyl)methyl)-4-pentene-1-methanol (69 mg, 0.3 mmol), BocNHOTs (103 mg, 0.36 mmol), triphenylphosphine (118 mg, 0.45 mmol), bis(4-chlorobenzyl)azodicarboxylate (165 mg, 0.45 mmol) to a reaction tube, replace the gas with nitrogen, add tetrahydrofuran (3 mL), and stir at 0°C for 4 to 8 h. Then, concentrate to dryness at low temperature, add dichloromethane (3 mL), and produce a white solid, which is filtered and the filtrate is collected and concentrated to dryness at low temperature.

[0186] (2) The crude product obtained above was directly dissolved in 2,2,2-trifluoroethanol (4.5 mL), 2,2,2-trifluoroacetic acid (3.4 μL, 0.05 mmol) was added, and the mixture was stirred at 60° C. for 4 to 8 h under nitrogen protection, and then cooled to room temperature.

[0187] (3) Potassium carbonate (83 mg, 0.6 mmol) was added to the reaction solution of step (2), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 3-allyl-5-methyl-5H-pyrido[3,2-b]indole (21 mg, 32%).

[0188] The reaction equation is:

[0189]

[0190] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0191] 1 H NMR (400MHz, DMSO-d6) δ8.32(d,J=1.5Hz,1H),8.16(d,J=7.8Hz,1H),7.81(d,J=1.3Hz,1H),7.64(d,J=8.3Hz,1H), 7.56–7.51(m,1H),7.25(t,J=7.4Hz,1H),6.12–6.01(m,1H),5.16–5.09(m,2H),3.87(s,3H),3.58(d,J=6.6Hz,2H). 13 C NMR(101MHz,DMSO-d6)δ141.8,141.5,139.1,137.6,134.2,132.1,127.2,1 21.2,119.8,119.5,116.3,116.0,109.7,37.2,28.9.ESI-HRMS(m / z):[M+H] + Calculate for C21 H 19 N2O:223.1230; found:223.1230.

[0192] Example 13 Synthesis of 4-phenyl-5H-pyrido[3,2-b]indole (W13)

[0193] The synthesis process is:

[0194] (1) Add tert-butyl (3-(3-indolyl)-3-phenylpropyl)(p-toluenesulfonyloxy)carbamate (148 mg, 0.29 mmol) and 2,2,2-trifluoroethanol (4.5 mL) to a reaction tube, add 2,2,2-trifluoroacetic acid (3.1 μL, 0.04 mmol), stir at 60°C for 4-8 h under nitrogen protection, and cool to room temperature.

[0195] (2) Potassium carbonate (80 mg, 0.58 mmol) was added to the reaction product of step (1), and the mixture was stirred at 40°C and exposed to air for 4 to 8 hours. The resulting reaction solution was concentrated and purified by silica gel column chromatography (eluent: petroleum ether / ethyl acetate = 5 / 1) to obtain 4-phenyl-5H-pyrido[3,2-b]indole (33 mg, 47%).

[0196] The reaction equation is:

[0197]

[0198] The obtained product was measured on a nuclear magnetic resonance instrument, and the obtained nuclear magnetic resonance data were:

[0199] 1 H NMR(400MHz,CD3OD)δ8.45(d,J=5.0Hz,1H),8.32–8.30(m,1H),7.78–7.75(m,2H) ,7.61–7.56(m,3H),7.52–7.48(m,2H),7.42(d,J=5.0Hz,1H),7.29–7.25(m,1H). 13 CNMR(101MHz,CD3OD)δ143.1,142.8,142.0,137.8,134.3,132.5,130.3,129 .9,129.5,129.1,122.5,121.5,121.0,120.6,113.0.ESI-HRMS(m / z):[M+H] + Calculate for C 17 H 13 N2:245.1073; found:245.1086.

[0200] Example 14 Activity Test

[0201] The concentration of cisplatin was 50 μM, and the concentration of the other compounds (W1-W12) was 20 μM. The following cancer cells or tumor cells (A549 human lung cancer cells, MKN-45 human gastric cancer cells, HCT116 human colon cancer cells, HeLa human cervical cancer cells, K-562 human chronic myeloid leukemia cells, 786-O human renal clear cell adenocarcinoma cells, TE-1 human esophageal cancer cells, 5637 human bladder cancer cells, GBC-SD human gallbladder cancer cells, L-02 human normal liver cancer cells, MCF7 human breast cancer cells, HepG2 human liver cancer cells, SF126 human brain tumor cells, DU145 human prostate cancer cells, CAL-62 human thyroid cancer cells, PATU8988T human pancreatic cancer cells, HOS human osteosarcoma cells, A-375 human malignant melanoma cells, A-673 human rhabdomyosarcoma cells, 293T human embryonic kidney cells) were tested for cytotoxic activity using the CCK-8 method. The results are as follows: Figure 1 As shown, W6 has a wide range of activities against different cancer cells or tumor cells.

[0202] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A delta-carboline compound, characterized in that: The general structural formula is shown in (I): Among them, R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 8 are any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group; R 5 It is any one of a hydrogen atom, an alkyl group, an aryl group, a heteroaryl group, a sulfonyl group, an acyl group, a carbonyl group, and an allyl group.

2. The δ-carboline compound according to claim 1, characterized in that: When the R 1 and / or R 2 and / or R 3 and / or R 4 and / or R 6 and / or R 7 and / or R 8 When each of the above R is alkyl, fluoroalkyl, aryl, fluoroaryl, heteroaryl, fluoroheteroaryl, hydroxyl, alkoxy, aryl ether, heteroaryl ether, thiol, alkyl thioether, aryl thioether, heteroaryl thioether, amino, alkylamino, arylamino, heteroarylamino, ester, acyl, amide, carbonyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, sulfonyl, sulfone and sulfoxide, the above R 1 and / or R 2 and / or R 3 and / or R 4 and / or R 6 and / or R 7 and / or R 8 Can be represented by one or more independent R X substituted by a substituent; When R 5 When R is any one of an alkyl group, an aryl group, a heteroaryl group, a sulfonyl group, an acyl group, a carbonyl group, and an allyl group, 5 Can be represented by one or more independent R X replace; The R X It is any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group.

3. The method for synthesizing a delta-carboline compound according to claim 1 or 2, characterized in that: Here are the steps: (1) stirring an indolehydroxylamine derivative in the presence of an organic solvent and a Bronsted acid for 0 to 96 hours, and cooling to room temperature; (2) The reaction solution of step (1) is stirred for 0 to 96 hours under the action of an oxidant and a base to obtain a δ-carboline compound.

4. The synthesis method according to claim 3, characterized in that: The synthesis process of the indolehydroxylamine derivative is as follows: indole propanol, activated hydroxylamine derivative, organic phosphine and azodicarboxylate are stirred in an organic solvent for 0 to 96 hours, and the obtained product is concentrated to dryness at low temperature to obtain the product.

5. The synthesis method according to claim 4, characterized in that: The equivalent ratio of the indolepropanol, the activated hydroxylamine derivative, the organic phosphine, and the azodicarboxylic acid ester is 1:0.01-20:0.01-20:0.01-20, the concentration of the organic solvent is 0.001-100 mol / L, and the reaction temperature is -100-200°C; In step (1), the equivalent ratio of the indolehydroxylamine derivative to the Bronsted acid is 1:0.01-20, the concentration of the organic solvent is 0.001-100 mol / L, and the reaction temperature is -100-200°C; In step (2), the equivalent ratio of the base to the indolehydroxylamine derivative is 1:0.01-20, and the reaction temperature is -100-200°C.

6. The synthesis method according to claim 4 or 5, characterized in that: The structural formula of the activated hydroxylamine derivative is: Among them, R 9 is any one of acyl, carbonyl, and sulfonyl; R 10 Any of sulfonyl and acyl; The organic phosphine is any one of triaryl phosphine, triheteroaryl phosphine, trialkyl phosphine, etc., or a mixture of any proportion of several of them; The azodicarboxylic acid ester is any one of dialkyl azodicarboxylate, diaryl azodicarboxylate and diheteroaryl azodicarboxylate or a mixture of any proportions of the above.

7. The synthesis method according to claim 6, characterized in that: When the R 9 When R is any one of acyl, carbonyl, and sulfonyl, 9 Can be one or more independent R X Replacement; when the R 10 When R is a sulfonyl group or an acyl group, 10 Can be one or more independent R X replace; And / or, the aryl, heteroaryl and alkyl groups in the triarylphosphine, triheteroarylphosphine and trialkylphosphine may be replaced by one or more independently R X replace; And / or, the alkyl, aryl, and heteroaryl groups in the dialkyl azodicarboxylate, diaryl azodicarboxylate, and diheteroaryl azodicarboxylate may be replaced by one or more independently selected R X replace; The R X It is any one of a hydrogen atom, an alkyl group, a fluoroalkyl group, an aryl group, a fluoroaryl group, a heteroaryl group, a fluoroheteroaryl group, a hydroxyl group, an alkoxy group, an aryl ether, a heteroaryl ether, a thiol group, an alkyl thioether, an aryl thioether, a heteroaryl thioether, an amino group, an alkylamino group, an arylamino group, a heteroarylamino group, an ester group, an acyl group, an amide group, a carbonyl group, an alkenyl group, a substituted alkenyl group, an alkynyl group, a substituted alkynyl group, a sulfonyl group, a sulfone group, and a sulfoxide group.

8. The synthesis method according to claim 4, characterized in that: The Bronsted acid is one or a mixture of any proportion of hydrochloric acid, sulfuric acid, nitric acid, acetic acid, trifluoroacetic acid, benzoic acid, and sulfonic acid; The base is any one of carbonate, bicarbonate, acetate, phosphate, hydrogen phosphate, potassium tert-butoxide, sodium tert-butoxide, lithium tert-butoxide, triethylamine, diisopropylethylamine, DBU, triarylamine, triheteroarylamine or any mixture thereof in any proportion; The organic solvent is any one of 2,2,2-trifluoroethanol, 2,2,2-trichloroethanol, 1,1,1,3,3,3-hexafluoro-2-propanol, chloroethanol, 2,2-dichloroethanol, dichloromethane, chloroform, acetonitrile, methanol, ethanol, tert-butanol, isopropanol, benzene, toluene, tetrahydrofuran, N,N-dimethylformamide, DMSO, 1,4-dioxane, 2-methyl-tetrahydrofuran, ether, and tert-butyl methyl ether, or a mixture of several solvents in any proportion. The oxidant is any one of O2, air, TEMPO, nitrogen oxides similar to TEMPO, ammonium oxide salts of nitrogen oxides, t-BuOOH, (t-BuO)2, NaOCl, diacetyl iodobenzene, bistrifluoroacetyl iodobenzene, DDQ, tetrachlorobenzoquinone, MnO2, SeO2, ammonium cerium nitrate, nitric acid, Pd / C and nitrogen oxides of amines; except O2 and air, the equivalent ratio of the oxidant to the indolehydroxylamine derivative is 1:0.01 to 20.

9. A pharmaceutical composition, characterized in that: The invention comprises the compound according to any one of claims 1 to 3 or the compound synthesized by the synthesis method according to any one of claims 4 to 8, or its stereoisomer, tautomer or salt, or its prodrug molecule and a medically acceptable carrier.

10. Use of the compound according to any one of claims 1 to 3, the compound synthesized by the synthesis method according to any one of claims 4 to 8, or the pharmaceutical composition according to claim 9 in the preparation of drugs for treating leukemia, cancer or tumors.